logo
  • Über uns
    • Über uns
    • Führungsteam
    • Partnerschaften
  • Technologie
    • Technologie
    • Produktion
    • Publikationen
  • Pipeline
  • Newsroom
    • News
    • Events
    • Downloads
  • Investor Relations
    • Überblick
    • Aktieninformation
    • Analysten-Coverage
    • Hauptversammlung 2022
    • Finanzberichte
    • Corporate Governance
    • E-Mail Alert
  • Karriere
    • Werden Sie Teil der RNA people
    • Ausbildung
    • Aktuelle Stellenangebote
  • DE

Mechanism of Action

mRNA-Based Vaccines and Mode of Action


by Bettina Joedicke-Braas

Unifying in vitro and in vivo IVT mRNA expression discrepancies in skeletal muscle via mechanotransduction


by Sovereign

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines


by Sovereign

mRNA mediates passive vaccination against infectious agents, toxins, and tumors


by Sovereign

A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects


by Sovereign

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response


by Sovereign

Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity


by Sovereign

An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs


by Sovereign

Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals


by Sovereign

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors


by Sovereign

  • 1
  • 2
  • 3
CureVac N.V.
Standort Tübingen, DeutschlandFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac AG
Standort Tübingen, DeutschlandHauptsitzFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac AG
Standort Frankfurt, DeutschlandKlinische EntwicklungSchumannstr. 2760325 FrankfurtT +49 69 7680 587 - 0F +49 69 7680 587 - 2222
CureVac Real Estate GmbH
Standort Tübingen, DeutschlandFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac Corporate Services GmbH
Standort Tübingen, DeutschlandFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac Inc.
Standort Boston, USA250 Summer St 3rd FlBoston, MA 02210, USAP +1 617 377404 - 0
CureVac Swiss AG
Standort Basel, SchweizWartenbergstraße 40CH-4052 BaselT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac RNA Printer GmbH
Standort Tübingen, DeutschlandFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac Belgium SA
Standort Ottignies-Louvain-la-Neuve, BelgienAv. Jean Monnet 41348 Ottignies-Louvain-la-Neuve
Social

© 2022 CureVac AG

KontaktImpressumDatenschutzerklärungAllgemeine Geschäftsbedingungen